Instituto Nacional de Cancerología

Running trials

• Recruiting

  Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries

  NCT07539844· AbbVie· Source

• Recruiting

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

  NCT07087054· Phase 3· Crinetics Pharmaceuticals Inc.· Source

• Recruiting

  A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  NCT07060807· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  NCT06925737· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  NCT06824467· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

  NCT06841354· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Amgen· Source

• Recruiting

  Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  NCT06393374· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

  NCT06117774· Phase 3· Amgen· Source

• Recruiting

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· Phase 3· Amgen· Source

• Active, not recruiting

  Quality of Life as a Predictor of OS and PFS in Patients With Lung Cancer

  NCT06900283· Instituto Nacional de Cancerologia, Columbia· Source

• Active, not recruiting

  S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

  NCT04155034· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

  NCT03939481· SWOG Cancer Research Network· Source

• Recruiting

  Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

  NCT03678025· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

  NCT03407144· Phase 2· Merck Sharp & Dohme LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ovarian cancer3 recruiting
• Prostate cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting

Closed trials

• Completed

  Effectiveness of Interventions for Improving HPV Vaccination Cover

  NCT07113236· Instituto Nacional de Cancerologia, Columbia· Source

• Terminated

  Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer

  NCT01048853· M.D. Anderson Cancer Center· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Cervical cancer36 works · 3 trials